Prestige Consumer Healthcare Inc. (NYSE:PBH) Insider Sells $735,585.95 in Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) insider William P’pool sold 8,987 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the sale, the insider now owns 20,058 shares of the company’s stock, valued at $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Prestige Consumer Healthcare Stock Performance

PBH opened at $82.36 on Friday. The firm has a market cap of $4.07 billion, a P/E ratio of 20.04, a PEG ratio of 2.32 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 1-year low of $56.61 and a 1-year high of $83.83. The company has a 50 day simple moving average of $73.29 and a two-hundred day simple moving average of $70.25. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. During the same quarter in the previous year, the firm earned $1.07 earnings per share. The company’s quarterly revenue was down .9% compared to the same quarter last year. Equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on PBH shares. DA Davidson restated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Jefferies Financial Group restated a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Moderate Buy” and an average price target of $83.67.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds have recently modified their holdings of the stock. Opal Wealth Advisors LLC purchased a new position in shares of Prestige Consumer Healthcare in the second quarter worth $26,000. Quest Partners LLC lifted its holdings in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after buying an additional 424 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Prestige Consumer Healthcare by 80.6% in the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after buying an additional 208 shares in the last quarter. Gladius Capital Management LP purchased a new position in shares of Prestige Consumer Healthcare in the second quarter worth $35,000. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after buying an additional 433 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.